Minnelide
Pancreatic Adenosquamous Carcinoma
National Cancer Institute (NCI)UNKNOWNPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
11 Active assets in the Pancreatic Adenosquamous Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Revolution Medicines, Inc. | Phase 3 | BB |
Fluorouracilum Revolution Medicines, Inc. | Phase 3 | BB |
Oxaliplatin Revolution Medicines, Inc. | Phase 3 | B |
Zoldonrasib Revolution Medicines, Inc. | Phase 3 | B |
Daraxonrasib Revolution Medicines, Inc. | Phase 3 | B |
View all 11 →
Same molecule, other indications
Minnelide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →